Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AMG 162: Phase II ongoing

One-year data from an ongoing U.S. Phase II trial in 411 women showed that AMG 162 increased BMD at the lumbar

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE